Bluejay Diagnostics, Inc. (BJDX) 10-Year Financial Performance & Capital Metrics

BJDX • • Industrial / General

HealthcareMedical DevicesDiagnostic & Imaging EquipmentPoint-of-Care Diagnostics

AboutBluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.Show more

Revenue $0
EBITDA -$7M +26.9%
Net Income -$8M +22.5%
EPS (Diluted) -42.08 +42.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -178.98% -29.8%
ROIC -399.92% +23.5%
Debt/Equity 0.04 -68.2%
Interest Coverage -8.71

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Shares diluted 33.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM20.23%

EPS CAGR

10Y-

5Y-

3Y-

TTM59.24%

ROCE

10Y Avg-3489.69%

5Y Avg-4091.66%

3Y Avg-118.59%

Latest-160.32%

Peer Comparison

Point-of-Care Diagnostics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
PAVMPAVmed Inc.	8.06M	8.75	17.64	22.15%	-217914.55%	-245.07%
SMLRSemler Scientific, Inc.	310.75M	20.33	3.96	-17.44%	130.8%	10.51%	0.00
BJDXBluejay Diagnostics, Inc.	1.18M	0.65	-0.02			-185.51%	0.04
HSCSHeartSciences Inc.	10.17M	3.20	-0.34	-76.61%	-1042.38%	-216.05%	14.55
LUCDLucid Diagnostics Inc.	163.87M	1.25	-1.19	79%	-8.6%	-404.1%	3.94
BMRABiomerica, Inc.	8.09M	2.68	-1.24	-1.92%	-90.29%	-90.76%	0.11
MDAISpectral AI, Inc.	49.41M	1.61	-1.89	63.83%	-70.64%
CODXCo-Diagnostics, Inc.	6.12M	2.92	-2.35	-42.53%	-63.36%	-80.8%	0.04

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	249.04K	0	0
Revenue Growth %	-	-	-	-	-1%	-
Cost of Goods Sold+	142.97K	157.04K	145.72K	200.13K	0	0
COGS % of Revenue	-	-	-	0.8%	-	-
Gross Profit+	-142.97K	-157.04K	-145.72K	48.91K	0	0
Gross Margin %	-	-	-	0.2%	-	-
Gross Profit Growth %	-	-0.1%	0.07%	1.34%	-1%	-
Operating Expenses+	1.63M	1.04M	3.08M	9.37M	10.31M	7.17M
OpEx % of Revenue	-	-	-	37.61%	-	-
Selling, General & Admin	1.18M	669.14K	2.08M	5.21M	4.6M	3.7M
SG&A % of Revenue	-	-	-	20.94%	-	-
Research & Development	454.61K	527.25K	1.15M	4.15M	5.71M	3.47M
R&D % of Revenue	-	-	-	16.67%	-	-
Other Operating Expenses	0	-157.04K	-145.72K	0	0	0
Operating Income+	-1.63M	-1.2M	-3.23M	-9.32M	-10.31M	-7.17M
Operating Margin %	-	-	-	-37.41%	-	-
Operating Income Growth %	-	0.27%	-1.7%	-1.88%	-0.11%	0.3%
EBITDA+	-1.49M	-1.04M	-3.08M	-9.01M	-9.53M	-6.97M
EBITDA Margin %	-	-	-	-36.18%	-	-
EBITDA Growth %	-	0.3%	-1.97%	-1.92%	-0.06%	0.27%
D&A (Non-Cash Add-back)	142.97K	157.04K	145.72K	306.37K	780.96K	199.1K
EBIT	-1.63M	-1.2M	-3.23M	-9.32M	-9.95M	-6.89M
Net Interest Income+	52.28K	116.67K	145.84K	89.67K	164.9K	-677.21K
Interest Income	52.28K	143.67K	513.3K	89.67K	164.9K	145.82K
Interest Expense	-	27K	367.46K	0	0	823.03K
Other Income/Expense	811.57K	38.11K	-258.13K	20.83K	357.33K	-548.18K
Pretax Income+	-819.84K	-1.16M	-3.49M	-9.3M	-9.95M	-7.72M
Pretax Margin %	-	-	-	-37.33%	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	0.92%	0.97%	1.07%	1%	1%	1%
Net Income+	-757.72K	-1.13M	-3.73M	-9.3M	-9.95M	-7.72M
Net Margin %	-	-	-	-37.33%	-	-
Net Income Growth %	-	-0.49%	-2.31%	-1.49%	-0.07%	0.22%
Net Income (Continuing)	-819.84K	-1.16M	-3.49M	-9.3M	-9.95M	-7.72M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-9.55	-14.19	-29.67	-73.22	-72.62	-42.08
EPS Growth %	-	-0.49%	-1.09%	-1.47%	0.01%	0.42%
EPS (Basic)	-9.55	-14.19	-29.67	-73.22	-72.62	-42.08
Diluted Shares Outstanding	79.34K	79.34K	125.7K	126.02K	137.06K	183.39K
Basic Shares Outstanding	79.34K	79.34K	125.7K	126.02K	137.06K	183.39K
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	300.34K	1.06M	20.66M	11.79M	3.22M	4.9M
Cash & Short-Term Investments	96.01K	912.36K	19.05M	10.11M	2.21M	4.3M
Cash Only	96.01K	912.36K	19.05M	10.11M	2.21M	4.3M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	645	0	0	0	41.27K	14.56K
Days Sales Outstanding	-	-	-	-	-	-
Inventory	123.51K	84.76K	0	0	0	0
Days Inventory Outstanding	315.3	197.01	-	-	-	-
Other Current Assets	69.92K	0	0	0	223.81K	-14.56K
Total Non-Current Assets+	616.18K	459.14K	358.38K	1.73M	1.65M	1.76M
Property, Plant & Equipment	611.56K	459.14K	332.75K	1.7M	1.62M	1.72M
Fixed Asset Turnover	-	-	-	0.15x	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	4.62K	4.62K	4.62K	4.46K	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	-4.62K	21.02K	30.75K	28.66K	35.26K
Total Assets+	916.52K	1.52M	21.02M	13.52M	4.87M	6.66M
Asset Turnover	-	-	-	0.02x	-	-
Asset Growth %	-	0.66%	12.85%	-0.36%	-0.64%	0.37%
Total Current Liabilities+	576.54K	1.85M	637.16K	1.64M	1.77M	810.37K
Accounts Payable	29.13K	374.93K	295.78K	635.82K	491.47K	145.12K
Days Payables Outstanding	74.35	871.43	740.87	1.16K	-	-
Short-Term Debt	265K	1.06M	0	0	0	113.26K
Deferred Revenue (Current)	86K	258.92K	0	0	0	0
Other Current Liabilities	196.41K	21.81K	0	4.81K	4.81K	4.81K
Current Ratio	0.52x	0.57x	32.43x	7.19x	1.82x	6.05x
Quick Ratio	0.31x	0.53x	32.43x	7.19x	1.82x	6.05x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	3.27M	3.88M	0	339.74K	202.31K	117.56K
Long-Term Debt	804.29K	0	0	0	0	0
Capital Lease Obligations	0	0	0	323.92K	189.99K	108.99K
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	2.47M	3.88M	0	15.82K	12.32K	8.57K
Total Liabilities	3.85M	5.72M	637.16K	1.98M	1.97M	927.92K
Total Debt+	1.07M	1.06M	0	492.62K	352.98K	222.25K
Net Debt	973.28K	143.55K	-19.05M	-9.62M	-1.86M	-4.08M
Debt / Equity	-	-	-	0.04x	0.12x	0.04x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-44.32x	-8.79x	-	-	-8.71x
Total Equity+	-2.93M	-4.21M	20.38M	11.54M	2.89M	5.73M
Equity Growth %	-	-0.43%	5.85%	-0.43%	-0.75%	0.98%
Book Value per Share	-36.96	-53.02	162.14	91.58	21.12	31.24
Total Shareholders' Equity	-2.93M	-4.21M	20.38M	11.54M	2.89M	5.73M
Common Stock	315	315	2.01K	2.02K	124	55
Retained Earnings	-2.93M	-4.21M	-7.69M	-17M	-26.95M	-34.67M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	-2.47M	-3.88M	0	0	0	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.69M	-508.71K	-4.37M	-7.74M	-8.31M	-7.82M
Operating CF Margin %	-	-	-	-31.09%	-	-
Operating CF Growth %	-	0.7%	-7.58%	-0.77%	-0.07%	0.06%
Net Income	-819.84K	-1.16M	-3.49M	-9.3M	-9.95M	-7.72M
Depreciation & Amortization	142.97K	157.04K	145.72K	306.37K	780.96K	199.1K
Stock-Based Compensation	14.81K	7.37K	68.46K	433K	189.25K	20.09K
Deferred Taxes	0	0	170.66K	0	0	0
Other Non-Cash Items	-849.78K	-111.1K	222.01K	237.45K	3.09K	312.03K
Working Capital Changes	-178.28K	596.26K	-1.49M	578.54K	666.73K	-633.19K
Change in Receivables	-645	645	0	0	0	0
Change in Inventory	-103.88K	38.75K	84.76K	0	0	0
Change in Payables	-25.21K	345.8K	-79.15K	298.88K	-235.76K	-346.35K
Cash from Investing+	-6.02K	0	-23.95K	-1.2M	-704.17K	-306.78K
Capital Expenditures	-6.02K	0	-23.95K	-1.2M	-704.17K	-306.78K
CapEx % of Revenue	-	-	-	4.82%	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	1.51M	1.33M	22.53M	8.07K	1.11M	10.22M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	-17.67K	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	100K	0	-513.47K	0	956.53K	-1.84M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-1.7M	-508.71K	-4.39M	-8.94M	-9.02M	-8.13M
FCF Margin %	-	-	-	-35.9%	-	-
FCF Growth %	-	0.7%	-7.63%	-1.04%	-0.01%	0.1%
FCF per Share	-21.38	-6.41	-34.93	-70.95	-65.79	-44.31
FCF Conversion (FCF/Net Income)	2.23x	0.45x	1.17x	0.83x	0.84x	1.01x
Interest Paid	46.07K	53.24K	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-46.12%	-58.25%	-137.9%	-178.98%
Return on Invested Capital (ROIC)	-	-	-	-429.68%	-522.84%	-399.92%
Gross Margin	-	-	-	19.64%	-	-
Net Margin	-	-	-	-3733.11%	-	-
Debt / Equity	-	-	-	0.04x	0.12x	0.04x
Interest Coverage	-	-44.32x	-8.79x	-	-	-8.71x
FCF Conversion	2.23x	0.45x	1.17x	0.83x	0.84x	1.01x
Revenue Growth	-	-	-	-	-100%	-

Frequently Asked Questions

Growth & Financials

Bluejay Diagnostics, Inc. (BJDX) grew revenue by 0.0% over the past year. Growth has been modest.

Bluejay Diagnostics, Inc. (BJDX) reported a net loss of $6.9M for fiscal year 2024.

Dividend & Returns

Bluejay Diagnostics, Inc. (BJDX) has a return on equity (ROE) of -179.0%. Negative ROE indicates the company is unprofitable.

Bluejay Diagnostics, Inc. (BJDX) had negative free cash flow of $6.3M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener